IRLAB participates at Aktiedagarna in Stockholm on June 9.

Gothenburg, Sweden, June 3, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces that CEO Kristina Torfgård and CFO Gustaf Albèrt will participate in Aktiespararna’s event Aktiedagarna in Stockholm.

IRLAB publishes interim report for the period January – March 2026

IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing